Neil L. Spector, MD (Chairman) is
Director of Translational Research in Oncology at Duke University
where he focuses on developing rationally targeted cancer therapies with a special emphasis on rare cancers such as
inflammatory breast cancer. In his previous position as director of
Exploratory Medical Sciences in Oncology at GlaxoSmithKline led the development of two new drugs: Nelarabine
and Tykerb.
Thomas F. DeLaney, MD is
Associate Professor of Radiation Oncology at Harvard
Medical School,
Co-Director of the Center for Sarcoma and Connective Tissue Oncology at
MGH and Medical Director of the Francis
H. Burr
Proton Therapy
Center at MGH where
he specializes in treating chordomas and other tumors of the spine.
Adrienne Flanagan, MD, PhD
is Professor of Musculoskeletal Pathology at
the University College London and Clinical Lead and consultant
histopathologist for the London Bone and Soft Tissue Sarcoma Unit, where
she runs an active research program in bone sarcomas with a particular
focus on chordoma. She published a seminal paper in 2006 that identified
brachyury as a nearly-pathognomonic biomarker for chordoma.
Fran Hornicek, MD, PhD is
Associate Professor in the Department of Orthopaedic Surgery at Harvard Medical School,
Co-Director of the Center for Sarcoma and Connective Tissue Oncology at
MGH and Chief of the Orthopaedic Oncology Service at MGH where he has one
of the nations largest surgical practices for chordomas of the axial spine.
He also coordinates a major cross-disciplinary chordoma research program
at MGH.
Michael J. Kelley, MD is Associate Professor of Medicine at Duke University
and Chief of Hematology and Oncology at the Durham VA Medical Center. His
lab has a major focus in chordoma, and he has collaborated with the NCI
for the past ten years on the familial chordoma study.
Paul Meltzer, MD, PhD
is a pediatric oncologist and Chief of the Genetics Branch of the
NCI’s Center for Cancer Research at NIH. He has led major genomic
profiling projects for multiple tumor types and has a special interest in
sarcomas.
Deric Park, MD is Assistant Professor in Neurology,
Hematology, Oncology and Neurosurgery at the University of Pittsburgh
Hillman Cancer Center. He coordinates a multidisciplinary research effort
focused on developing novel treatments for glioma, chordoma and other skull-base
tumors.